Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Ascentage Pharma Group International ( (HK:6855) ) is now available.
Ascentage Pharma Group International has announced a supplemental notice for its Annual General Meeting scheduled for May 19, 2025, in Suzhou, China. The meeting will address additional resolutions concerning amendments to the company’s RSU Schemes and Share Option Scheme, as well as the approval of limits on shares issued under these schemes. These resolutions are significant for the company’s governance and could impact its operational strategies and stakeholder interests.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing therapies for cancer, hepatitis B, and age-related diseases. The company is listed on the Hong Kong Stock Exchange and operates primarily in the pharmaceutical industry, with a market focus on innovative drug development.
YTD Price Performance: 8.58%
Average Trading Volume: 4,255,328
Technical Sentiment Signal: Sell
Current Market Cap: HK$17.04B
For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.